Compare Enveric Biosciences Inc (ENVB) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Xylem, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Xylem, Inc. trades at $125.01 (market cap $28.86B). The key difference: Xylem, Inc. is far larger — about 5424.8× Enveric Biosciences Inc's market cap, and Xylem, Inc. pays a 1.42% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | XYL | |
|---|---|---|
Market Cap | $5.32M | $28.86B |
Sector | Health | Industrials |
52-Week High | $17.40 | $152.95 |
52-Week Low | $1.28 | $106.34 |
Enterprise Value | $408.82K | $30.12B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Xylem (XYL) trades at $121.55, up 0.28% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income reaching $957M and a 10.79% margin. Recent news highlights partnerships and leadership changes, while analyst consensus targets $152.00 with 47.5% buy ratings.
The stock offers growth potential from water infrastructure demand and margin expansion, but risks include competitive pressures and macroeconomic sensitivity. Institutional sentiment is mixed, with a balanced buy/hold split. Upside hinges on continued execution and Q2 2026 earnings due July 28.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
